Stocks and Investing
Stocks and Investing
Thu, September 7, 2023
[ 12:00 AM ] - WOPRAI
Wed, September 6, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Vikram Purohit Maintained (ASND) at Hold with Increased Target to $113 on, Sep 6th, 2023
Vikram Purohit of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Hold with Increased Target from $109 to $113 on, Sep 6th, 2023.
Vikram has made no other calls on ASND in the last 4 months.
There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tiago Fauth of "Credit Suisse" Initiated at Hold and Held Target at $89 on, Wednesday, June 14th, 2023
This is the rating of the analyst that currently disagrees with Vikram
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $152 on, Thursday, June 1st, 2023
Contributing Sources